A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy
Latest Information Update: 28 Jan 2021
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Adverse reactions; Registrational
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 29 Apr 2016 Results of a post-hoc analysis published in the Clinical Therapeutics
- 23 Apr 2014 New trial record